(NASDAQ: BBNX) Beta Bionics's forecast annual revenue growth rate of 28.05% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.24%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.54%.
Beta Bionics's revenue in 2026 is $119,013,000.On average, 14 Wall Street analysts forecast BBNX's revenue for 2026 to be $6,143,791,793, with the lowest BBNX revenue forecast at $5,819,866,040, and the highest BBNX revenue forecast at $6,385,836,315. On average, 14 Wall Street analysts forecast BBNX's revenue for 2027 to be $8,243,010,635, with the lowest BBNX revenue forecast at $7,274,832,550, and the highest BBNX revenue forecast at $9,164,399,446.
In 2028, BBNX is forecast to generate $11,451,225,287 in revenue, with the lowest revenue forecast at $10,265,747,008 and the highest revenue forecast at $13,226,968,272.